So, CEO Pearlman sells nearly $400,000 worth of stock back in September 2012 over $10 per share, but he and the company's bankers waited until the stock fell to $4.00 to arrange a Secondary Offering for MDGN. THAT IS A LOAD OF #$%$. And, that's why this stock has languished. Selfish management, over-diluting existing shareholders, while we wait for clinical trial results.
Pearlman needs to be held accountable for this. Why wasn't the company prepared to do a stock offering in double digits, where MDGN traded for over 6 months back in 2012?
I want to load up on MDGN because of the technology, but this financing fiasco is still #$%$ me off!!!